Genecast Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $4.76M

  • Investors
  • 13

Genecast General Information

Description

Developer of cancer diagnostic technology equipment designed to detect, diagnose and treat early-stage cancer. The company's technology amplifies only mutated genes while leaving the normal genes intact and its liquid biopsy method analyzes mutant tumor DNA in the blood, allowing cancer patients to be treated through a fast, accurate, and effective treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Office 10006, 10007 Garden 5 Techno Hall
  • 66 Chungmin-ro, Songpa-gu
  • Seoul
  • South Korea
+82
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Other Healthcare Technology Systems
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Office 10006, 10007 Garden 5 Techno Hall
  • 66 Chungmin-ro, Songpa-gu
  • Seoul
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genecast Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 23-Feb-2023 $4.76M Completed Generating Revenue
3. Early Stage VC (Series B) 08-Jun-2020 Completed Generating Revenue
2. Early Stage VC (Series A) 01-May-2018 $4.85M $4.85M Completed Startup
1. Seed Round 01-Dec-2017 Completed Startup
To view Genecast’s complete valuation and funding history, request access »

Genecast Patents

Genecast Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2020531044-A Dna polymerizing enzyme with increased gene mutation specificity and pcr buffer composition for increasing its activity Active 12-Jul-2017
EP-3653729-A1 Dna polymerase with increased gene mutation specificity and pcr buffer composition for increasing activity thereof Pending 12-Jul-2017
JP-6986299-B2 Dna polymerizing enzyme with increased gene mutation specificity and pcr buffer composition for increasing its activity Active 12-Jul-2017
US-20200149018-A1 Dna polymerase with increased gene mutation specificty and pcr buffer composition for increasing activity thereof Active 12-Jul-2017
EP-3653729-A4 Dna polymerase with increased gene mutation specificity and pcr buffer composition for increasing activity thereof Pending 12-Jul-2017 C12N9/1252
To view Genecast’s complete patent history, request access »

Genecast Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genecast Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Bio Corporation Minority
DK&D Corporation Minority
GC Biopharma Corporation Minority
GC Medis Venture Capital Minority
KB Investment Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Genecast FAQs

  • When was Genecast founded?

    Genecast was founded in 2016.

  • Where is Genecast headquartered?

    Genecast is headquartered in Seoul, South Korea.

  • What is the size of Genecast?

    Genecast has 29 total employees.

  • What industry is Genecast in?

    Genecast’s primary industry is Diagnostic Equipment.

  • Is Genecast a private or public company?

    Genecast is a Private company.

  • What is Genecast’s current revenue?

    The current revenue for Genecast is .

  • How much funding has Genecast raised over time?

    Genecast has raised $21.3M.

  • Who are Genecast’s investors?

    Access Bio, DK&D, GC Biopharma, GC Medis, and KB Investment are 5 of 13 investors who have invested in Genecast.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »